Barzolvolimab Clears Every Hurdle in Two Phase 3 CSU Trials
CLDX has more than doubled off its 52-week low of $22.1.
Summary
Barzolvolimab met the primary and all key secondary endpoints in two Phase 3 CSU trials, showing best-in-disease complete response rates and a favorable safety profile. BLA submission is planned for 2027.
Key Events · Product Development and Regulatory · CLDX
-
Phase 3 EMBARQ-CSU1 and CSU2 Meet All Endpoints
Both trials met the primary endpoint of mean change in UAS7 at Week 12 (LS mean change -20.2 to -20.5 for active arms vs -10.7 to -11.4 for placebo, p<.00001) and all key secondary endpoints.
-
Unprecedented Complete Response Rates
Complete response (UAS7=0) at Week 12 reached 42.4-45.7% for active arms vs 9.3-12.6% for placebo, deepening to 45.1-54.0% at Week 24 vs 15.4-17.6% placebo.
-
Efficacy in Omalizumab-Refractory and Severe Patients
In omalizumab-refractory CSU, complete response rates were 41.7-55.3% for active arms vs 9.3-15.1% placebo. Angioedema resolution (AAS7=0) reached 62.7-74.3% vs 33.7-33.8% placebo.
-
Favorable Safety Profile Through 24 Weeks
Barzolvolimab was well-tolerated with a safety profile consistent with prior Phase 2 experience through the 24-week placebo-controlled period.
Analysis · CLDX · Life Sciences
Barzolvolimab delivered best-in-disease efficacy in both Phase 3 EMBARQ-CSU trials, meeting the primary endpoint and every key secondary endpoint with high statistical significance. Complete response rates of 42-54% versus 9-18% for placebo at Weeks 12 and 24 are unprecedented in CSU, and the drug showed clear benefit in omalizumab-refractory patients and those with severe angioedema. With a BLA submission planned for 2027, this de-risks the company's lead asset and positions it for a commercial launch in a large underserved market. The stock is trading near its 52-week high, reflecting the market's anticipation of this outcome.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 41.9% of the 322 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLDX was trading at $45.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $22.10 to $45.14. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.